Guillermo Sanz Santillana
Guillermo Sanz (Spain; 1957), Valencia, Spain. He has authored or coauthored more than 300 papers and 30 book chapters. His main topics of interest are myelodysplastic syndromes (MDS; molecular biology, prognostic markers & treatment) and allogeneic hematopoietic cell transplantation, especially umbilical cord blood transplantation, modality in which his center has performed more than 400 transplants. He has made important contributions to the development of the International Prognostic Scoring System and its revised version and the International consensus criteria for evaluating response to treatment in MDS. Guillermo has been thr President of the Spanish MDS cooperative group (GESMD, 2005 – 2018), leads the clinical trials of the Spanish PETHEMA cooperative group for MDS patients, and has served as scientific chair of the 14th International Symposium on MDS (Valencia, May 2017). Currently Dr. Guillermo Sanz is co-chairing two european projects: HARMONY and HARMONY PLUS, both under the umbrella of HARMONY Alliance on the use of Big Data for Better Outcomes for Hematologic Malignancies of the Innovative Medicines Initiative. Both initiatives are a public-private partnership, equally supported by the European Commission & the EFPIA. HARMONY (2017-2021) counts with 53 partners and is supported with 40 million € while HARMONY PLUS (2020-2023) is supported with 11.8 million € and counts with 39 partners. HARMONY Alliance is considered the star European project in the field.